Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success

First Progress In Frontline DLBCL In 20 Years

 
• By Andrew McConaghie

Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.

Roche_Basel
While CAR-Ts grabbed the headlines when launched several years ago, Roche's Polivy looks set to have a greater impact on DLBCL treatment.

More from Business

More from Scrip